Sponsors (2)
The bill would cap what many Americans pay for covered drugs and anchor U.S. prices to lower foreign prices—substantially improving affordability for patients—while creating material risks to pharmaceutical investment, potential cost-shifts to employers/insurers, and added administrative and research-priority pressures on government agencies.
Millions of public program enrollees and other patients (Medicare, Medicaid, CHIP, VA, TRICARE, FEHB, uninsured and commercially insured patients with chronic conditions) would pay no more than a set annual reference price for covered drugs, directly lowering out-of-pocket costs and improving affordability.
Anchoring U.S. drug prices to lower prices in a set of developed reference countries is likely to push list prices down across the market, reducing overall drug spending for patients and payers.
Civil penalties collected from manufacturers for noncompliance would be redirected to the NIH, increasing available funding for drug research and development without new direct appropriations.
Large financial penalties and reduced manufacturer revenues could lead firms to raise launch prices, scale back R&D investment, or delay/limit development of some new therapies, potentially slowing patient access to innovations.
Manufacturers might respond to price constraints by increasing list prices on other products or restricting supply, which could cause insurers and employers to face higher premiums or cost-shifting that ultimately affects workers and small businesses.
HHS would face substantial administrative complexity and ongoing workload to set annual reference prices for every drug and assess international comparators, risking delays, regulatory burden, and implementation challenges.
Based on analysis of 2 sections of legislative text.
Requires HHS to set annual reference prices for all prescription drugs and caps retail list prices for federal program enrollees and all buyers at that reference price, with penalties for noncompliance.
Introduced May 14, 2025 by Debbie Dingell · Last progress May 14, 2025
Requires the HHS Secretary to set an annual reference price for every prescription drug and caps retail list prices for people in major federal health programs at no more than that reference price. If manufacturers charge more, they must offer the drug at the reference price to all buyers (including uninsured and commercially insured) and face heavy civil penalties; penalty proceeds are routed to NIH for drug research. Also establishes the act's short title. The main effect is a government-set price cap tied to international reference pricing and a broad requirement that manufacturers make drugs available at that price to all purchasers.